The positive recommendation from the SRC to escalate the trial to a higher dose without any observed dose-limiting toxicities is a significant milestone for Pasithea Therapeutics. This suggests that the drug is well-tolerated at current doses, which is a positive indicator for its continued development. Such news is likely to boost investor confidence and positively impact the stock price in the short term.